Boston Scientific Corporation (BSX)
| Market Cap | 64.79B |
| Revenue (ttm) | 10.12B |
| Net Income (ttm) | 201.00M |
| Shares Out | 1.42B |
| EPS (ttm) | 0.37 |
| PE Ratio | 123.58 |
| Forward PE | 28.17 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 30 |
| Last Price | $45.60 |
| Previous Close | $45.32 |
| Change ($) | 0.28 |
| Change (%) | 0.62% |
| Day's Open | 45.19 |
| Day's Range | 45.01 - 45.93 |
| Day's Volume | 9,108,233 |
| 52-Week Range | 32.99 - 46.03 |
Final Trades: Salesforce, Amazon, Boston Scientific & more
The "Halftime Report" traders give their top picks to watch for the second half.
Boston Scientific (NYSE:BSX) shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. The company also issued FY21 EPS guidance with a midpoint above analyst e...
Organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in Q2.
Boston Scientific (BSX) delivered earnings and revenue surprises of 8.11% and 4.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.1 billion in Q2 of 2021, beating the estimate of $2.9 billion. Sales increased 53.6% Y/Y on a reported basis and 52.4% on an organic b...
Shares of Boston Scientific (NYSE:BSX) fell 1.0% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 400.00% year over year to $0.40, which beat t...
MARLBOROUGH, Mass., July 27, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.077 billion during the second quarter of 2021, growing 53.6 percent on a reported ba...
Boston Scientific (BSX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Boston Scientific is scheduled to report its Q2 2021 results on Tuesday, July 27. We expect Boston Scientific to report revenues and earnings in-line with the consensus estimates, driven by a rebound in...
Strong procedure recovery and market share gains across many of the businesses and regions are expected to have boosted Boston Scientific's (BSX) Q2 sales.
The stock price of Boston Scientific reached its 52-week high of $44 in April this year before a recent sell-off in broader markets, which led to a 7% drop in BSX stock to levels of around $41 currentl...
MARLBOROUGH, Mass., July 21, 2021 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive 24-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the n...
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Barron's, a famous weekly financial newspaper, organizes an annual roundtable with prominent U.S. investors where they discuss the market and give their opinions on their best ideas for stocks.
NVST vs. BSX: Which Stock Is the Better Value Option?
MARLBOROUGH, Mass., June 29, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter e...
Boston Scientific (BSX) currently holds an equity stake of roughly 27%.
MARLBOROUGH, Mass., June 24, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of David S.
The following are the best-performing stocks over the past six months that have a long-term presence in more than five gurus' portfolios.
MARLBOROUGH, Mass., June 24, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Farapulse, Inc. The acquisition wil...
We believe that the stock price of Boston Scientific (NYSE: BSX) is undervalued at current levels of $43. BSX stock is up 65% from the levels of around $26 it was at on March 23, 2020, underperforming ...
Which one of these medical device makers is better poised for a breakout year?
The European market release of Boston Scientific's (BSX) EXALT Model B Single-Use Bronchoscope will mitigate infection risks associated with reusable imaging scopes.
With the trading day more than halfway over, the markets had dipped after a relatively strong start to the day.
Company to begin limited market release in Europe in June MARLBOROUGH, Mass., May 25, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has completed CE Mark for the EXAL...
Big call buying in Boston Scientific
"Halftime Report" trader Pete Najarian spots unusual activity in the options market
MARLBOROUGH, Mass., May 24, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 37th Annual Strategic Decisions Conference on Friday, June 4, 2021.
MARLBOROUGH, Mass., May 18, 2021 /PRNewswire/ -- Data presented at hotline and late-breaking trial sessions today at the EuroPCR 2021 congress demonstrated positive procedural performance, including low...
The stock price of Boston Scientific has corrected 3.5% over the last five trading sessions, and the dip appears to be a good buying opportunity in our view. Not only did the company post an upbeat perf...
Investors are optimistic about Boston Scientific (BSX) owing to its solid first-quarter performance and impressive value-added acquisitions.
Like most medical device manufacturers, Boston Scientific Corp. ( BSX , Financial) also witnessed a slowdown in 2020 on account of the lower demand for medical devices and the deferral of elective surge...
MARLBOROUGH, Mass., (May 3, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.
Rapid innovation is boosting the robotic surgery space, putting the spotlight on Johnson & Johnson (JNJ), Stryker (SYK), Boston Scientific (BSX), Intuitive Surgical (ISRG) and Asensus Surgical (ASXC).
Bulls bet on Boston Scientific and Las Vegas Sands
"Halftime Report" trader Pete Najarian spots unusual activity in the options market
Boston Scientific Corporation (NYSE: BSX) Q1 sales grew by 5.9% (organically) to $2.75 billion, beating the previous guidance range between negative 3% and 3% in the quarter, better than the consensus e...
Boston Scientific (BSX) registers strong sequential improvement in overall financial performance in Q1.
Boston Scientific (BSX) delivered earnings and revenue surprises of 23.33% and 5.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
MARLBOROUGH, Mass., April 28, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.752 billion during the first quarter of 2021.
Boston Scientific (BSX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Within Boston Scientific's (BSX) coronary therapies, drug-eluting stents sale continue to be a challenge from a pricing standpoint in Q1.
Boston Scientific (BSX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EVP&Pres, Periph Intervent of Boston Scientific Corp (30-Year Financial, Insider Trades) Jeffrey B. Mirviss (insider trades) sold 28,123 shares of BSX on 04/15/2021 at an average price of $40.95 a share.
Final Trades: Northrop Grumman, Boston Scientific, Nvidia & more
The "Halftime Report" traders give their top picks to watch for the second half.
Boston Scientific's (BSX) TheraSphere is expected to be used as a safe and effective treatment option for numerous HCC patients worldwide on the back of positive trial results.
MARLBOROUGH, Mass., March 26, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter e...
Boston Scientific (BSX) currently expects its 2021 organic revenues to include a headwind of $62 million from 2020 LOTUS Edge sales.
About BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and r... [Read more...]
| Industry Medical Devices | IPO Date May 18, 1992 |
| CEO Michael Mahoney | Employees 38,000 |
| Stock Exchange NYSE | Ticker Symbol BSX |
Analyst Forecasts
According to 27 analysts, the average rating for BSX stock is "Strong Buy." The 12-month stock price forecast is 48.97, which is an increase of 7.39% from the latest price.